A Crisis of Confidence, How India’s ‘Pharmacy of the World’ is Failing its Own People

A Crisis of Confidence, How India’s ‘Pharmacy of the World’ is Failing its Own People

India’s pharmaceutical industry stands as a monument to the nation’s scientific and manufacturing prowess. Dubbed the “Pharmacy of the World,” it is the third-largest by volume, supplying affordable generic medicines and vaccines to over 200 countries, particularly the developing world. This title is a source of immense national pride, a symbol of India’s capacity to heal and provide. Yet, a series of devastating, preventable tragedies has exposed a grotesque duality—a world-class export machine underpinned by a shockingly negligent domestic regulatory framework. The recurring specter of toxic cough syrups killing children, both at home and abroad, reveals a systemic “quality control disease” that threatens to shatter global trust and, more tragically, continues to cost young Indian lives.

The recent deaths of at least 20 children in Madhya Pradesh since September 2nd, linked to a toxic cough syrup, follow a grim and familiar script. The state’s drug controller has been transferred, three officials suspended, and a local medic, Praveen Soni, arrested. This reactive scramble is a pattern, a tragic pantomime that plays out after every poisoning, only to be forgotten until the next crisis. This latest incident is not an anomaly; it is a symptom of a deep-rooted and chronic failure in India’s drug regulation, a failure where corruption, political apathy, and a blatant disregard for citizen safety have created an environment where poisonous substances are dispensed as medicine with terrifying regularity.

A Global and National History of Negligence

The poison in question, Diethylene Glycol (DEG), is a toxic industrial solvent never meant for human consumption. Its history as a lethal adulterant in medicines is long and entirely preventable. The first large-scale tragedy occurred in the United States in 1937, when over 100 people died. The American response was swift and decisive. Public outrage spurred the U.S. Congress to pass the groundbreaking Federal Food, Drug, and Cosmetic Act of 1938, which mandated rigorous safety testing before a drug could be marketed. The result? The U.S. has never witnessed a mass DEG poisoning since.

For India and other developing nations, however, DEG poisoning has become a recurring nightmare. The article by Amitav Banerjee catalogs a horrifying global toll: 7 children in South Africa (1969), 91 in Nigeria (1990), 28 in Bangladesh (1990-92), 29 in Argentina (1992), 75 in Haiti (1996), and over 400 in Panama (2007).

Disturbingly, India’s own domestic record is a litany of avoidable death. Prior to the recent Madhya Pradesh tragedy, India had suffered multiple large-scale DEG poisonings:

• Madras, 1972: 18 children killed.

• Mumbai’s J.J. Hospital, 1986: 14 patients killed.

• Bihar, 1989: 11 lives claimed.

• Gurgaon, 1998: 35 children died.

• Rajnagar, Jammu, 2009: 12 children killed.

This pattern demonstrates that for over five decades, the Indian system has been aware of this specific, deadly threat and has consistently failed to eradicate it.

The Ugly Double Standard: Export vs. Domestic Safety

The crisis took on an international dimension in 2022 when Made-in-India cough syrups were linked to mass child deaths abroad. The World Health Organization (WHO) issued a global alert after 68 children in Gambia died of acute kidney failure linked to syrups from Haryana-based Maiden Pharmaceuticals. The following month, 16 children in Uzbekistan died, with the source traced to Uttar Pradesh-based Marion Biotech.

The Indian government’s response to these international incidents was telling. In the Gambia case, it defensively claimed the WHO’s data was “inadequate” and its own tests found no contaminants. However, in the Uzbekistan case, a Central Drugs Standard Control Organization (CDSCO) inspection did confirm “manufacturing violations,” leading to the permanent cancellation of Marion Biotech’s license in March 2023. Shockingly, this “permanent” cancellation was reversed by the Uttar Pradesh government just seven months later, in October 2023, allowing the company to resume production of most other products.

This episode highlights a corrosive double standard. Stung by international pressure and the threat to a $50 billion export industry, the government made testing mandatory for cough syrups before export in 2022. This was a pragmatic move to protect its global reputation and economic interests. However, as Banerjee pointedly asks, “Are the lives of Indian children cheaper than those abroad?” No such mandatory testing protocol exists for drugs sold within India. The same syrup that is tested for safety before being shipped to Africa can be sold untested to Indian families, revealing a brutal hierarchy of human life in the eyes of regulators.

The Anatomy of a Systemic Failure

The roots of this crisis are not mysterious; they are deeply embedded in the system’s structure and culture.

1. Regulatory Collapse and Corruption:
The CDSCO and state drug control authorities are chronically understaffed, underfunded, and plagued by corruption. The ratio of drug inspectors to manufacturing facilities is “woefully inadequate,” making effective oversight impossible. Many small pharmaceutical companies lack even basic testing facilities, relying on fraudulent certificates of analysis. They “get away due to corruption and nexus with regulators,” with oversight being “thrown out of the window.”

2. Political and Judicial Apathy:
The system is steeped in a culture of impunity. Rather than strengthening regulations, the recent Jan Vishwas Act of 2023 amended the Drugs and Cosmetics Act of 1940 to allow manufacturers of spurious drugs to escape imprisonment by paying a fine. This transforms a criminal act of endangering public health into a mere cost of doing business, effectively incentivizing malpractice.

The fate of the landmark Lentin Commission Report is a classic example of this apathy. Formed after the 1986 J.J. Hospital deaths, the 289-page report was a “scathing indictment” that called for a major overhaul of the public health administration. Its recommendations were largely ignored. The subsequent criminal trial dragged on for so long that most of the accused have now died of old age, with no one ever being held truly accountable.

3. A Broken Safety Net at Every Level:

• Doctors: In resource-poor settings, medics like Praveen Soni face pressure to prescribe affordable drugs, often with no access to safety alerts or a drug’s manufacturing track record.

• Pharmacists: Often act as mere dispensers rather than the final line of defense, failing to counsel patients or question prescriptions.

• Patients and Families: Lack awareness and accessible information in local languages to question medication safety or recognize warning signs of poisoning.

A Prescription for Reform: Rebuilding the “Pharmacy of the World” from Within

To restore trust and prevent future deaths, India needs a paradigm shift from reactive scandal-management to proactive, uncompromising safety governance.

1. Urgent Regulatory Overhaul:

• Mandatory Testing for All: The export-quality testing protocol must be immediately applied to all drugs meant for the domestic market.

• Unannounced Inspections and Market Surveillance: The CDSCO must be granted more resources and authority to conduct surprise audits and routinely test random batches of drugs from the market, not just factories.

• Severe and Unambiguous Penalties: The Jan Vishwas Act’s provisions for spurious drugs must be repealed. Criminal liability with mandatory imprisonment for executives of companies found responsible for deaths must be enacted.

2. Strengthening the Regulatory Infrastructure:

• Invest in State Labs: State drug testing laboratories require massive investment in equipment and trained personnel to reduce backlogs and ensure reliable results.

• National Adverse Event Reporting System: A robust, accessible, and mandatory system for doctors and pharmacists to report side effects in real-time is crucial for early detection of problematic drugs.

3. Building a Culture of Quality and Accountability:

• Industry Responsibility: The pharma industry’s associations must move beyond defensive posturing and actively police their members, championing quality as a non-negotiable core value.

• Judicial Expediency: Special fast-track courts must be established to handle cases of spurious drugs to ensure justice is delivered within a reasonable timeframe.

• Public Awareness: Nationwide campaigns in local languages are needed to empower citizens to be vigilant about their medications.

Conclusion: A Moral and Economic Imperative

The line between a life-saving medicine and a lethal poison is terrifyingly thin. In India, that line is currently drawn by neglect, corruption, and a fatal lack of political will. The title “Pharmacy of the World” is not a divine right; it is a privilege earned through relentless adherence to quality and safety. That privilege is now hanging in the balance.

The recurring deaths of children from DEG poisoning are not just public health failures; they are a profound moral crisis. They force the nation to confront an uncomfortable question: in its rush to become an economic superpower, has it decided that some of its citizens are expendable? If India wishes to truly be a developed nation and a trusted global leader in medicine, it must first prove that it values the life of every child in Madhya Pradesh as much as it values a export contract. The world is watching, but more importantly, India’s own people are waiting. The cure for this quality control disease is known; what is lacking is the will to administer it.

Q&A: Deepening the Understanding of India’s Pharma Crisis

1. The article highlights a “double standard” where export drugs are tested but domestic ones are not. Why would the government and industry enforce stricter standards for other countries than for its own citizens?

This double standard is driven by a stark cost-benefit calculus:

• Economic Consequences: A failure in the export market triggers immediate international alerts from the WHO, import bans from dozens of countries, and devastating reputational damage that threatens the entire $50 billion pharmaceutical export industry. The economic cost of inaction is direct and massive.

• Political and Legal Consequences Domestically: Within India, the consequences are tragically diluted. The political fallout from the deaths of poor children in a single district can often be contained through short-term administrative actions (transfers, suspensions) and political maneuvering. The legal process, as seen with the Lentin Report, is so slow and inefficient that corporate executives almost never face meaningful criminal liability. The domestic cost of negligence is perceived as lower than the cost of implementing universal, stringent testing.

2. The Lentin Commission Report after the 1986 tragedy provided a clear roadmap for reform. Why have its recommendations been largely ignored for decades?

The Ignoring of the Lentin Report is a classic case of systemic inertia and vested interests. The report likely recommended measures that threatened the status quo:

• Challenging Powerful Interests: Its call for a major overhaul would have necessitated taking on a powerful nexus of politically connected manufacturers, corrupt officials within the drug control administration, and a complacent political class.

• Administrative and Financial Burden: Implementing its recommendations—strengthening regulatory bodies, hiring thousands of new inspectors, funding state-of-the-art labs—requires significant and sustained financial investment and administrative willpower, which successive governments have lacked.

• Lack of Sustained Public Pressure: While each tragedy causes public outrage, it is often localized and short-lived. Without a sustained, nationwide civil society movement focused specifically on drug safety, the political pressure to act on a comprehensive report fades quickly, allowing the system to revert to its dysfunctional norm.

3. Beyond the central regulators (CDSCO), what is the role of State Drug Controllers, and how does this fractured system contribute to the problem?

India’s drug regulation is a fractured, dual-control system, which is a fundamental flaw.

• Licensing: The power to license manufacturing units for drugs meant for within the state lies with the State Drug Controller.

• Standard Setting: The CDSCO is responsible for approving new drugs and setting overall standards.
  This division creates critical vulnerabilities:

• A Race to the Bottom: A manufacturer denied a license in a state with stricter controls can simply shop around and obtain one from a state with a more pliable or corrupt regulatory office. This is why companies like Marion Biotech (UP) and Steam Pharmaceuticals (TN) can continue operating.

• Inconsistent Enforcement: Standards and enforcement rigor vary wildly from state to state, creating a patchwork of regulation full of holes.

• Blame Shifting: When a crisis occurs, the central and state governments can engage in a blame game, avoiding accountability.

4. The Jan Vishwas Act of 2023 replaces imprisonment with fines for certain offenses. Why is this particularly dangerous in the context of spurious drugs?

The Jan Vishwas Act, while perhaps well-intentioned for decriminalizing minor business infractions, is catastrophic for drug safety. Replacing imprisonment with fines for manufacturing spurious drugs is effectively legalizing negligence for a price.

• It’s a Cost-Benefit Analysis: For a profitable pharmaceutical company, a fine becomes a calculable business expense. If the profit from skipping quality tests and using cheap, toxic solvents like DEG is greater than the potential fine, the rational business decision is to cut corners.

• Removes the Deterrent: Criminal liability and the threat of jail time for company owners and executives are the only real deterrents against knowingly endangering lives. A fine does not carry the same moral stigma or personal consequence.

• Signals Government Priorities: It sends a clear message that the government prioritizes “ease of doing business” over the “safety of its citizens,” fundamentally undermining the regulatory philosophy.

5. For an ordinary Indian citizen, what practical steps can they take to protect themselves and their families from spurious medicines, given the current regulatory environment?

While the ultimate responsibility lies with the regulator, citizens can adopt a defensive, vigilant approach:

• Buy from Reputable Sources: Always purchase medicines from large, well-known, and physically clean pharmacies with a long-standing reputation. Avoid dubious-looking chemists or unverified online platforms.

• Check for Authenticity: Look for the mandatory QR code on the packaging, which can be scanned to verify the drug’s authenticity via government portals.

• Inspect the Packaging: Look for signs of tampering, spelling mistakes on the label, poor print quality, or missing batch numbers and manufacturing/expiry dates.

• Be Observant of the Product: Look for unusual color, smell, consistency, or sedimentation in syrups and suspensions.

• Ask the Pharmacist: Engage with the pharmacist. Ask questions about the manufacturer and any potential side effects. A reputable pharmacist should be able to counsel you.

• Report Adverse Effects: If you or your family experience unexpected or severe side effects after taking a medication, report it immediately to your doctor and consider filing a complaint with the state drug control authority. Citizen vigilance is a crucial, if inadequate, supplement to failed official oversight.